Corpus Intelligence IC Memo — EL CAMINO HOSPITAL 2026-04-26 05:02 UTC
IC Memo — EL CAMINO HOSPITAL
Investment Committee Memorandum | CA | 388 beds | Grade B | EBITDA uplift $98.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

EL CAMINO HOSPITAL

CCN 050308 | SANTA CLARA, CA | 388 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

EL CAMINO HOSPITAL is a 388-bed suburban community hospital in SANTA CLARA, CA with $1.34B in net patient revenue and a 11.7% operating margin. The hospital serves a payer mix of 31.7% Medicare, 2.6% Medicaid, and 65.7% commercial.

Thesis: Platform Growth. Our ML models identify $98.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 11.7% to 19.1% (+736bps).

Net Revenue HCRIS$1.34B
Current EBITDA COMPUTED$156.9M
Operating Margin COMPUTED11.7%
Occupancy HCRIS71.5%
Revenue / Bed COMPUTED$3.4M
Net-to-Gross HCRIS23.7%
Distress Probability ML40.0%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
145
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 11.7% places it above the state median. Among 145 size-comparable peers (194-776 beds), the median margin is -4.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (194-776), prioritizing same-state peers. 145 hospitals in the comp set.

HospitalStateBedsRevenueMargin
EL CAMINO HOSPITAL (Target)CA388$1.34B11.7%
STANFORD HEALTH CARECA657$6.76B3.7%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
UCSD MEDICAL CENTERCA718$3.06B-7.2%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
LOS ANGELES GENERAL MEDICAL CECA596$1.96B10.2%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $98.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$28.1M+210bp18mo
Cost to Collect4.5%2.5%$26.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$26.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$16.3M+122bp9mo
Clean Claim Rate88.0%96.0%$856K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$28.1M
Cost to Collect
$26.8M
Denial Rate Reduction
$26.5M
A/R Days Reduction
$16.3M
Clean Claim Rate
$856K
Total EBITDA Uplift$98.5M
Current EBITDA$156.9M
+ RCM Uplift+$98.5M
Pro Forma EBITDA$255.4M
Current Margin11.7%
Pro Forma Margin19.1%
WC Released (1x)$51.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$241.4M$2.02B8.37x52.9%
Base (11x exit)10.0x11.0x$241.4M$2.30B9.53x57.0%
Bull Case9.0x11.0x$217.3M$2.70B12.44x65.6%
Bull (12x exit)9.0x12.0x$217.3M$3.01B13.87x69.2%
Bear Case11.0x10.0x$265.6M$1.45B5.46x40.4%
Bear (11x exit)11.0x11.0x$265.6M$1.68B6.33x44.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 145 hospitals with 194-776 beds
  • Same-state prioritization (n=146)
  • Comp margins: P25=-15.9% / P50=-4.5% / P75=3.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.